[Brainlife] Newsletter, Vol.3 No.19, 12 Jun 2004

top

BRAINLIFE NEWSLETTER

Volume 3, Number 19 - 12 June 2004	Volume 3 Archive


Contents

	Diagnosis & Evaluation
	Overall Management
	Prognosis & Outcome
	Treatment


Diagnosis & Evaluation

	S. M. Kurian, E. B. Crowell Concordance of FDG-PET scan and MRI- spectroscopy in primary and metastatic intracranial tumors 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1551 (Clinical Study)

Overall Management

	G. Shah, S. Kesari, R. Xu, J. Henson, T. Batchelor, F. Hochberg, A. Oneill, B. Levy, J. Bradshaw, P. Y. Wen Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1523 (Clinical Study)

Prognosis & Outcome

	B. S. Abdulkarim, A. Hasbini, J. Cougnard, L. Djafari, C. Lacroix, F. Parker, C. Haie, C. Cioloca, E. Deutsch, E. Raymond Baseline pathological and radiological assessment of tumor angiogenesis predicts survival in patients with oligodendrogliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1545 (Clinical Study)

Treatment

	G. Cairncross, W. Seiferheld, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, W. Curran An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1500 (Clinical Study)
	A. Chakravarti, W. Seiferheld, H. I. Robins, A. Guha, D. Brachman, W. Curran, A. Choucair, M. Mehta An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1571 (Clinical Study)
	C. Conrad, H. Friedman, D. Reardon, J. Provenzale, E. Jackson, H. Serajuddin, D. Laurent, B. Chen, W. K. A. Yung A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1512 (Clinical Study)
	F. G. El Kamar, L. M. Deangelis, J. Yahalom, D. D. Correa, B. W. Grant, R. V. Larocca, J. J. Raizer, D. Schiff, L. E. Abrey Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1518 (Clinical Study)
	H. A. Fine, L. Kim, C. Royce, S. Mitchell, J. P. Duic, P. Albert, L. Musib, D. Thornton A phase II trial of LY317615 in patients with recurrent high grade gliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1511 (Clinical Study)
	P. Hau, T. Jauch, B. Hirschmann, E. Drechsel, O. Grauer, H. Koch, C. Wismeth, A. Steinbrecher, U. Bogdahn Adjuvant chemotherapy with temozolomide and pegylated liposomal doxorubicin in the first-line therapy of patients with glioblastoma – a phase-II trial 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1547 (Clinical Study)
	M. Holdhoff, K. A. Kreuzer, C. Appelt, R. Scholz, A. Jordan, B. Hildebrandt, C. A. Schmidt, R. A. Van Etten, B. Dörken, P. Le Coutre Combined administration of imatinib mesylate and ionizing radiation leads to increased radiosensitivity in the human glioblastoma cell line RuSi RS1 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1564 (Cell Culture Study)
	J. Ikeda, H. Kobayashi, N. Ishii, Y. Sawamura, H. Aoyama, H. Shirato Combination chemotherapy with gemcitabine and docetaxel for recurrent germ cell tumors in the central nervous system 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1540 (Clinical Study)
	K. A. Jaeckle, K. Ballman, J. Uhm, J. O'Fallon, P. Schomberg, B. Scheithauer, C. Giannini, P. J. Flynn, J. Buckner Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1525 (Clinical Study)
	D. Y. Kim, K. W. Lee, T. Yun, J. H. Kim, D. W. Kim, S. A. Im, T. Y. Kim, D. S. Heo, Y. J. Bang, N. K. Kim Efficacy of platinum-based chemotherapy after cranial irradiation in patients with brain metastasis from non-small cell lung cancer 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1575 (Clinical Study)
	D. A. Loblaw, L. Holden, A. Xenocostas, S. Chander, P. Cooper, P. C. Chan, E. X. Chen, C. S. Wong Erythropoietin cerebrospinal concentrations and functional outcomes after a single intravenous infusion of epoetin alfa in patients with malignant extradural spinal cord compression 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1548 (Clinical Study)
	H. Nakagawa, M. Tamura, Y. Fukushima, S. Majima Continuous intrathecal chemotherapy with 5-fluoro-2'-deoxyuridine (FdUrd) in treatment of leptomeningeal carcinomatosis 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1566 (Clinical Study)
	A. J. Newman, J. Fiveash, S. Rosenfeld, M. Johnson, R. Diasio, W. Wang, A. Cockrell-Donohue, L. B. Nabors A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No. 1537 (Clinical Study)
	A. M. P. Omuro, J. J. Raizer, L. E. Abrey A phase I trial of temozolomide and vinorelbine in patients with recurrent brain metastases 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No. 1567 (Clinical Study)
	D. Peereboom, K. Carson, D. Lawson, G. Lesser, J. Supko, S. Grossman, The New Approaches to Brain Tumor Therapy (NABTT) Consortium A phase I/II trial of BMS-247550 for patients with recurrent high-grade gliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1546 (Clinical Study)
	J. J. Raizer, L. E. Abrey, P. Wen, T. Cloughesy, I. A. Robins, H. A. Fine, F. Lieberman, V. K. Puduvalli, K. L. Fink, M. Prados A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1502 (Clinical Study)
	D. Reardon, H. Friedman, W. K. A. Yung, M. Brada, C. Conrad, J. Provenzale, E. Jackson, H. Serajuddin, B. Chen, D. Laurent A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM) 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1513 (Clinical Study)
	H. I. Robins, M. Won, C. Schultz, A. Choucair, D. Brachman, W. Demas, M. Mehta A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1529 (Clinical Study)
	L. Scopece, G. Cavallo, E. Palmerini, E. Franceschi, A. Paioli, F. Spagnolli, S. Rimondini, R. Conforti, R. Degli Esposti, L. Crino Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1562 (Clinical Study)
	J. Sgouros, S. Upadhyay, M. Braun, M. Holmes, A. Maraveyas A phase I study of chemo-radiotherapy using gemcitabine as a radiosensitiser in patients with metastases to the brain 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No. 1570 (Clinical Study)
	R. Soffietti, A. Costanza, E. Laguzzi, M. Nobile, R. Rudà; A phase II study of first-line temozolomide and second-line PCV in recurrent/progressive malignant gliomas 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1574 (Clinical Study)
	R. Stupp, W. P. Mason, M. J. Van Den Bent, M. Weller, B. Fisher, M. Taphoorn, A. A. Brandes, G. Cairncross, D. Lacombe, R. O. Mirimanoff Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group 40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.2 (Clinical Study)

bottom